MBA MBA - Immuneering Corp President, CoFounder
| IMRX Stock | USD 2.13 0.08 3.90% |
Insider
MBA MBA is President, CoFounder of Immuneering Corp
| Age | 39 |
| Address | 245 Main Street, Cambridge, MA, United States, 02142 |
| Phone | 617 500 8080 |
| Web | https://immuneering.com |
Immuneering Corp Management Efficiency
The company has return on total asset (ROA) of (0.3742) % which means that it has lost $0.3742 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6181) %, meaning that it created substantial loss on money invested by shareholders. Immuneering Corp's management efficiency ratios could be used to measure how well Immuneering Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.59 in 2024. Return On Capital Employed is likely to drop to -0.65 in 2024. Non Currrent Assets Other is likely to rise to about 1.1 M in 2024, whereas Total Assets are likely to drop slightly above 97.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Vicky Hahne | Celcuity LLC | 58 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Jonathan JD | Compass Therapeutics | N/A | |
| Peter Moesta | Compass Therapeutics | N/A | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Richard MD | Gossamer Bio | 63 | |
| David Chao | Centessa Pharmaceuticals PLC | 56 | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| Joshua MBA | Centessa Pharmaceuticals PLC | 50 | |
| Jean Franchi | Replimune Group | 58 | |
| Francis Conway | Larimar Therapeutics | N/A | |
| Vered MBA | Compass Therapeutics | 53 | |
| Lance Laing | Celcuity LLC | 62 | |
| FACC Facc | NewAmsterdam Pharma | 65 | |
| FESC MD | NewAmsterdam Pharma | 68 | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Winston MBA | Pmv Pharmaceuticals | 48 | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Irena Konstantinova | Inventiva Sa | N/A | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.37 |
Immuneering Corp Leadership Team
Elected by the shareholders, the Immuneering Corp's board of directors comprises two types of representatives: Immuneering Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immuneering. The board's role is to monitor Immuneering Corp's management team and ensure that shareholders' interests are well served. Immuneering Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immuneering Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dr MBA, President CoFounder | ||
| Mallory CPA, Principal Fin | ||
| Praveen Nair, Head VP | ||
| Mohamedi MBA, Head Devel | ||
| Leah Neufeld, Chief Officer | ||
| Brett Hall, Chief Officer | ||
| Harold Brakewood, Chief Officer | ||
| Paula CPA, Director Controller | ||
| Scott MD, Chief Officer | ||
| Peter King, Head VP | ||
| MS MBA, CoFounder Emeritus | ||
| Michael JD, Chief Secretary | ||
| MBA MBA, President, CoFounder | ||
| Rajaraman Krishnan, Head Discovery |
Immuneering Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immuneering Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | 19.72 M | ||||
| Shares Outstanding | 31.05 M | ||||
| Shares Owned By Insiders | 29.12 % | ||||
| Shares Owned By Institutions | 30.11 % | ||||
| Number Of Shares Shorted | 2.04 M | ||||
| Price To Book | 1.15 X | ||||
| Price To Sales | 563.62 X | ||||
| Revenue | 455 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.